A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

被引：0
|
作者：
Nazha, Aziz [1 ]
Kantarjian, Hagop [1 ]
Borthakur, Gautam [1 ]
Kadia, Tapan M. [1 ]
Faderl, Stefan [1 ]
Ravandi, Farhad [1 ]
Estrov, Zeev [1 ]
Jabbour, Elias [1 ]
Quintas-Cardama, Alfonso [1 ]
Cortes, Jorge E. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6589
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Nazha, Aziz
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Faderl, Stefan
    Estrov, Zeev
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [2] Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
    Strati, Paolo
    Kantarjian, Hagop
    Ravandi, Farhad
    Nazha, Aziz
    Borthakur, Gautam
    Daver, Naval
    Kadia, Tapan
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Rajkhowa, Trivikram
    Durand, Menda
    Andreeff, Michael
    Levis, Mark
    Cortes, Jorge
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (04) : 276 - 281
  • [3] PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH 5-AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
    Daver, N.
    Cortes, J.
    Ravandi, F.
    Basu, S.
    Garcia-Manero, G.
    Jabbour, E.
    Pemmaraju, N.
    Hendrickson, S.
    Pierce, S.
    Ning, J.
    Gonzales, G.
    Konopleva, M.
    Andreeff, M.
    Borthakur, G.
    Bueso-Ramos, C.
    Blando, J.
    Allison, J.
    Kantarjian, H.
    Sharma, P.
    HAEMATOLOGICA, 2016, 101 : 42 - 43
  • [4] A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Daver, Naval
    Boddu, Prajwal
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    DiNardo, Courtney
    Konopleva, Marina
    Pemmaraju, Naveen
    Kadia, Tapan
    Jain, Nitin
    Pierce, Sherry
    Hussain, Nawar
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Basu, Sreyashi
    Cortes, Jorge
    Sharma, Padmanee
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S6 - S7
  • [5] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    BLOOD, 2012, 120 (21)
  • [6] Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Pemmaraju, Naveen
    Bhalla, Kapil N.
    Daver, Naval
    Wilson, Nathaniel R.
    Fiskus, Warren C.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Burger, Jan A.
    Short, Nicholas J.
    Alvarado, Yesid
    Jain, Nitin
    Masarova, Lucia
    Verstovsek, Srdan
    Issa, Ghayas C.
    Qiao, Wei
    Khoury, Joseph D.
    Pierce, Sherry A.
    Miller, Darla
    Konopleva, Marina
    Kantarjian, Hagop
    Borthakur, Gautam
    BLOOD, 2021, 138
  • [7] Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)
    Daver, Naval
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Cortes, Jorge E.
    Ravandi, Farhad
    Jabbour, Elias J.
    Pierce, Sherry
    Ning, Jing
    Konopleva, Marina
    Andreeff, Michael
    Kornblau, Steven M.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Bueso-Ramos, Carlos E.
    Lopez, Juliana Elisa Hidalgo
    Blando, Jorge
    Allison, James
    Kantarjian, Hagop M.
    Sharma, Padmanee
    BLOOD, 2016, 128 (22)
  • [8] PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
    Daver, N.
    Basu, S.
    Garcia-Manero, G.
    Cortes, J.
    Ravandi, F.
    Jabbour, E.
    Pemmaraju, N.
    Hendrickson, S.
    Gordon, T.
    Brandt, M.
    Pierce, S.
    Matthews, J.
    Kornblau, S.
    Flores, W.
    Konopleva, M.
    Kantarjian, H.
    Sharma, P.
    HAEMATOLOGICA, 2017, 102 : 176 - 177
  • [9] Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
    Williams, Casey B.
    Kambhampati, Suman
    Fiskus, Warren
    Wick, Jo
    Dutreix, Catherine
    Ganguly, Siddartha
    Aljitawi, Omar
    Reyes, Ruben
    Fleming, Allan
    Abhyankar, Sunil
    Bhalla, Kapil N.
    McGuirk, Joseph P.
    PHARMACOTHERAPY, 2013, 33 (12): : 1341 - 1352
  • [10] A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission
    Bazinet, Alexandre
    Kantarjian, Hagop
    Borthakur, Gautam
    Yilmaz, Musa
    Bose, Prithviraj
    Jabbour, Elias J.
    Alvarado, Yesid
    Chien, Kelly S.
    Pemmaraju, Naveen
    Takahashi, Koichi
    Short, Nicholas J.
    Issa, Ghayas C.
    Jain, Nitin
    Ferrajoli, Alessandra
    Burger, Jan A.
    Linderman, Debra Bull
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
12345